Rilexine® Palatable Tablets are only available under Veterinary Authorisation.

First generation cephalosporin for skin infections

Now registered for ONCE daily administration*

choice

The

Virbac Dermatology

www.virbac.co.nz

Rilexine® Palatable Tablets

Rilexine® Palatable Tablets are particularly adapted to treat pyoderma due to:

• Excellent diffusion and persistence in

the skin

• Good oral bioavailability

• Broad spectrum of activity with a very

high efficacy against gram+ve bacteria

• Good tolerability during long term use

• Once daily dosing and palatability for

ease of administration

Good compliance is essential for the successful treatment of pyoderma.

The risk of therapeutic failure is

relatively high in pyoderma as the

minimal duration of antibiotic treatment

for pyoderma is about three weeks.

This duration is recognised as a factor

contributing to a lack of compliance,

particularly as treatment should be

extended for a week beyond healing as

assessed clinically.

Compliance is improved when

medications are administered once daily

rather than 2 or more times a day1. Pet

owner compliance directly impacts the

probability of therapeutic success.

Once daily dosing and palatable tablets = better compliance

Prescribing Rilexine® Palatable Tablets

will make administration easier for pet

owners, reduce the risk of administration

problems and increase compliance

• Registered for once daily

administration (30mg/kg) for the

treatment of superficial pyoderma

in dogs

• Highly palatable to improve

acceptance of the medication by dogs

and cats

Rilexine® Palatable TabletsThe first generation, first line treatment for pyoderma

Cephalexin is considered the antibiotic of first choice for treating pyoderma.

Weight (kg) 75mg 300mg 600mg

2.5kg 1 tablet

5kg ½ tablet

10kg 1 tablet

20kg 1 tablet

30kg 1½ tablets

40kg 2 tablets

• Administration with food can be of benefit if the higher dose is less tolerated in rare cases.

• In cases of canine deep pyoderma and refractory cases of superficial pyoderma, dose should be doubled (60mg/kg once daily).

Rilexine® Palatable Tablets are also registered in dogs and cats for treatment of respiratory, digestive and urinary infections.

*Rilexine® Palatable Tablets are registered for once daily administration at 30mg/kg in the treatment of pyoderma in dogs and the treatment of lower urinary tract infections in cats and dogs. In cases of canine deep pyoderma and refractory cases of superficial pyoderma, dose should be doubled (60mg/kg once daily). For all other indications a dose rate of 10-20mg/kg every 12 hours should be administered.

Further reading: More Rilexine® Palatable Tablets Once a Day Efficacy Studiesi. Guaguère E., Maynard L., Salomon C., and Coll. Cephalexin

in the treatment of canine pyoderma: comparison of two dose rates. 3rd World Congress of Veterinary Dermatology, Edinburgh Sept. 1996

ii. Guaguère E., Salomon C., Cadot P. and Jasmin P. Comparison of two protocols of administration of cephalexin in the treatment of deep pyoderma in dogs. 4th World Congress of Veterinary Dermatology, San Francisco, Aug. 2000. Published in Veterinary Dermatology 2000, 11, 14-40.

iii. Maynard L., Guaguère E., and Medaille. Clinical effi cacy of cephalexin administered once or twice daily by oral route in the treatment of superficial pyoderma in dogs. 18th ESVD-

ECVD Annual Congress Nice, Sept. 2002

References1. Cals JWL., Hopstaken RM., Le Doux PHA., Driessen

GA., Nelmans PJ., Dinant GJ. Dose timing and patient compliance with two antibiotic treatment regimes for lower respiratory tract infections in primary care. International Journal of Antimicrobial Agents, 2008. 31 (6) 531-536

2. Toma S, Colombo S, Cornegliani L, Persico P, Galzerano M, Gianino MM, Noli C. (2008) Efficacy and tolerability of once daily cephalexin in canine superficial pyoderma- an open controlled study. Journal of Small Animal Practice 49(8) 384-391

3. Salomon C., Guaguère E. and Maynard L. Comparison of two dose rates of cephalexin in the treatment of superficial pyoderma in dogs. 15th ESVD Congress, Maastricht, Sept. 1998.

4. Lucas R., Sanches C., Flocke M., Pelgrini G., and Reme C. Efficacy of three Cefalexin regimens for the treatment of superficial folliculitis in dogs. 6th World Congress of Veterinary Dermatology, Hong Kong Nov. 2008.

5. Papich M.G. Clinical pharmacology of cephalosporin antibiotics. JAVMA, 1984, 184, 344-347.

6. Cardoniga R. et al., Penetration of antibiotic into interstitial tissue fluid following parenteral administration of lysin cephalexin. Drug Res. 1979, 29, 1547-1549.

7. Virbac, data on file.

8. Mason I. Antibiotic selection in practice. 17th ESVD Congress, Copenhagen, 2001.

9. Bousquet E., Ganière J.P., Ruvoen N., Larrat M. Post-antibiotic effect of cephalexin against isolates of Staphylococcus intermedius obtained from cases of canine pyoderma. Veterinary Dermatology 1999, 10, 253-255.

10. Odenholt-Tornqvist I. et al. Pharmacodynamic effects of subinhibitory concentrations of β-lactam antibiotics in vitro. Antimicrobial agents and chemotherapy, 35, 9, 1834-1839

Dose chart for the treatment of superficial pyoderma in dogs

30mg/kg ONCE DAILY

Rilexine® Palatable Tablets

Virbac New Zealand Ltd26 – 30 Maui Street, Pukete, Hamilton, 3200, New Zealandwww.virbac.co.nz 0800 847 222 (0800 VIRBAC) Fax: 09 272 7667

1. Excellent diffusion and persistence in the skin

• Rilexine® Palatable Tablets are

concentrated in extra-cellular fluids,

where Staphylococci are located and

grow in the skin5.

• Increased half life at the site of

infection: the half-life of Rilexine®

Palatable Tablets are 4 times higher

in interstitial tissue compared to the

plasma half life6.

2. High skin concentration• Higher skin concentrations of Rilexine®

Palatable Tablets when given as

30mg/kg dose orally compared to

those recorded with the 15 mg/kg

dose7.

• Increased concentration of Rilexine®

Palatable Tablets may be found in the

skin of dogs affected by pyoderma,

since inflamed tissues have an

increased blood flow8.

3. Post-antibiotic effect• Delayed re-growth of bacteria

following exposure to an antimicrobial

agent, even where the antibiotic

concentration falls below the MIC

(minimum inhibitory concentration) for

a period of time.

• A post-antibiotic effect of cephalexin

was recorded against Staphylococcus

intermedius isolated from cases of

canine pyoderma.

• This effect can delay re-growth of

Staph.intermedius for over three

hours, and increases with the drug

concentration9.

4. Sub-inhibitory effects• It has been demonstrated that

β-lactam antibiotics in sub-inhibitory

concentrations can still inhibit the

growth of staphylococci especially

if the bacteria have already been

exposed to the antibiotics10.

• In the animal, antibiotic concentration

lower than the MIC may still favour

elimination of pathogens by specific

and non-specific immunity10.

Rilexine® Palatable Tablets presents

cephalexin in a formulation that is

clinically proven to be efficacious at a

dose rate of 30mg/kg Once a Day. No

other cephalexin tablet has the same

comprehensive range of supporting

clinical evidence and studies as Rilexine®

Palatable Tablets.

Clinical efficacy of a drug depends on

the active ingredient, its concentration

and the formulation. Formulation is a key

element in determining the efficacy of a

product at a particular dose rate and

frequency.

Conclusions drawn from clinical trials are

only valid for the particular formulation

used in the trial or where bioequivalence

has been demonstrated.

As such the data presented on the use

of Rilexine® Palatable Tablets Once a

Day cannot be extrapolated to other

cephalexin tablets and their use once

daily cannot be justified without clinical

evidence.

Proven efficacy once a day

Rilexine® Palatable Tablets

Not all cephalexins are the same

This proven clinical efficacy can be explained by:

Clinically proven efficacy

ProtocolA multi-centric randomised clinical field trial. 51 dogs of various ages and breeds presenting with superficial bacterial

folliculitis were included in the study. Animals in the trial were allocated into 3 treatment groups:

• Rilexine® Palatable Tablets 30 mg/kg SID (15 dogs)

• Rilexine® Palatable Tablets 30 mg/kg BID (20 dogs)

• Rilexine® Palatable Tablets 15 mg/kg BID (16 dogs)

All animals were examined weekly until remission for a maximum of 5 weeks.

ResultsStaph. intermedius was identified in 66.7% of cases. Clinical cure

was achieved in 86.7% of cases in dogs treated with Rilexine®

Palatable Tablets 30mg/kg SID after 5 weeks treatment. The time

to clinical cure was not significantly different between groups.

ConclusionRilexine® Palatable Tablets 30mg/kg Once a Day proved to be as effective as 30mg/kg twice daily in the treatment of superficial folliculitis.

Superficial folliculitisEfficacy of three cephalexin regimes for the treatment of superficial folliculitis in dogs4.

Trial one

Rilexine® Palatable Tablets

Dispensing envelopes boost compliance

Blistered packs maintain tablet quality and freshness.

Rilexine®Palatable Tablets

30 mg/kg SID

Rilexine® Palatable Tablets

30 mg/kg BID

Rilexine®Palatable Tablets

15 mg/kg BID

86.7 85.0 81.3

Superficial PyodermaEfficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study2.

Trial three

ProtocolA multi-centric, controlled and randomised clinical trial was performed in 14 veterinary practices.

147 dogs from 3 months to 13 years old, with a clinical diagnosis of superficial pyoderma,

were included in the trial. Animals in the trial were allocated into 3 treatment groups:

• Group C1: Rilexine® Palatable Tablets 30 mg/kg SID (48 dogs)

• Group C2: Rilexine® Palatable Tablets 15 mg/kg BID (45 dogs)

• Group ACA: Amoxicillin + Clavulanic acid 12.5 mg/kg BID (54 dogs)

All animals were examined weekly for a minimum 28 days and treated until 10 days after a clinical cure was established

with a maximum treatment period of 60 days.

ResultsStaphylococci spp were implicated in 67.7% of cases. Clinical cure

was achieved in 91.7% of dogs treated with Rilexine® Palatable

Tablets 30mg/kg SID compared with only 75.9% of dogs treated

with ACA.

ConclusionA single daily dose of Rilexine® Palatable Tablets was found to be very effective in the treatment of canine superficial pyoderma.

ProtocolA multi-centric, controlled and randomised open study. 40 dogs from 8 months to 15 years old, with a clinical diagnosis of

superficial pyoderma, were included in the trial. Animals in the trial were allocated into 2 treatment groups:

• Group A: Rilexine® Palatable Tablets 30-40 mg/kg SID (20 dogs)

• Group B: Rilexine® Palatable Tablets 15-30 mg/kg BID (20 dogs)

All animals were examined every two weeks until two weeks after treatment discontinuation. Cephalexin was administered

orally until 14 days beyond clinical cure (maximum treatment duration of two months).

ResultsStaphylococcus intermedius was identified in 72.5% of cases. No significant differences were observed when the groups

were compared for clinical scores at days 14, 28 or 42. Nor were there any significant differences for time to cure and

percentage cured between the two groups.

ConclusionThis clinical trial shows that once daily Rilexine® Palatable Tablets are as effective as twice daily Rilexine® Palatable Tablets in the treatment of canine superficial pyoderma.

Superficial PyodermaComparison of two dose rates of cephalexin in the treatment of superficial pyoderma in dogs3.

Trial two

Rilexine® Palatable Tablets

30 mg/kg SID

Rilexine®Palatable Tablets

15 mg/kg BID

Amoxicillin + Clavulanic Acid 12.5 mg/kg BID

91.7 93.3 75.9